Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EBT: 2016-2025

Historic EBT for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$179.5 million.

  • Ultragenyx Pharmaceutical's EBT fell 34.78% to -$179.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$576.7 million, marking a year-over-year decrease of 2.79%. This contributed to the annual value of -$567.6 million for FY2024, which is 6.72% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported EBT of -$179.5 million as of Q3 2025, which was down 57.49% from -$114.0 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's EBT registered a high of -$72.8 million during Q3 2021, and its lowest value of -$238.8 million during Q3 2022.
  • For the 3-year period, Ultragenyx Pharmaceutical's EBT averaged around -$147.2 million, with its median value being -$149.8 million (2025).
  • Its EBT has fluctuated over the past 5 years, first plummeted by 574.02% in 2021, then soared by 33.42% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's EBT (Quarterly) stood at -$124.8 million in 2021, then declined by 24.20% to -$155.0 million in 2022, then increased by 18.12% to -$126.9 million in 2023, then declined by 5.13% to -$133.4 million in 2024, then slumped by 34.78% to -$179.5 million in 2025.
  • Its EBT stands at -$179.5 million for Q3 2025, versus -$114.0 million for Q2 2025 and -$149.8 million for Q1 2025.